Posted by Michael Wonder on 12 Mar 2025
Sydnexis announces FDA acceptance of new drug application and PDUFA date for SYD-101 for the treatment of progression of paediatric myopia
11 March 2025 - Sydnexis today announced that the US FDA has accepted its new drug application for SYD-101 and has assigned a PDUFA target action date of 23 October 2025.
If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of paediatric myopia in the US.
